ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Graff Discusses Sipuleucel-T in Patients With mCRPC

Julie Graff, MD
Published: Friday, Dec 08, 2017



Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Sipuleucel-T is well tolerated in this population, says Graff. Some patients have some itching or a slight fever, but both are both easily managed.

Although it has shown benefit, one of the challenges with sipuleucel-T is that it does not shrink tumors, Graff adds.


Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Sipuleucel-T is well tolerated in this population, says Graff. Some patients have some itching or a slight fever, but both are both easily managed.

Although it has shown benefit, one of the challenges with sipuleucel-T is that it does not shrink tumors, Graff adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x